The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Makhnovich E.V.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Kovalenko E.A.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Potential biomarkers of early diagnosis of Alzheimer’s disease
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9): 7‑14
Views: 3010
Downloaded: 170
To cite this article:
Bogolepova AN, Makhnovich EV, Kovalenko EA, Osinovskaya NA. Potential biomarkers of early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry.
2022;122(9):7‑14. (In Russ.)
https://doi.org/10.17116/jnevro20221220917
Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain, in which there are cognitive and behavioral disorders, but also visual impairment can occur. Deposits of beta-amyloid (Aβ) were also found in the retina of AD patients. At the same time, primary open-angle glaucoma (POAG) occupies the first place among geronto-ophthalmic pathologies in patients with AD. POAG, like AD, is a neurodegenerative disease. AD and POAG have common symptoms, and therefore several common principles for their early diagnosis can be developed. Therefore, a promising direction is the search for biomarkers for the early detection of AD and POAG. Currently, the diagnosis of early AD biomarkers in cerebrospinal fluid and biomarkers in the brain (imaging of amyloid plaques and tau positron emission tomography) are well studied, while data in literature on using these biomarkers in patients with POAG is scarce. However, the above diagnostic methods are not considered in routine clinical practice due to their invasiveness and high cost. There is a growing need for conventional, affordable biomarkers for AD and POAG, as it is necessary to start treatment of prodromal conditions from symptoms to onset of symptoms. In this connection, biomarkers such as Aβ and tau protein in blood serum and plasma are actively evaluated in patients with AD. In patients with POAG, there is no published data on studies of these biomarkers, which requires scientific research. Many authors discover the role of sirtuins (SIRT) in aging and age-related diseases, such as AD, glaucoma, age-related macular degeneration, and others. Possibly, SIRT could become potential biomarkers of neurodegenerative diseases.
Keywords:
Authors:
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Makhnovich E.V.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Kovalenko E.A.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies
Received:
18.02.2022
Accepted:
06.04.2022
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.